TCIIF yields 0.63% · JNJ yields 2.13%● Live data
📍 TCIIF pulled ahead of the other in Year 1
Combined, TCIIF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TCIIF + JNJ for your $10,000?
Tracsis plc, together with its subsidiaries, provides software and hardware products, and consultancy services for the rail industry. The company operates in two segments, Rail Technology and Services; and Data, Analytics, Consultancy & Events. The Rail Technology & Services segment provides a suite of operational software products covering timetabling, resource and rolling stock planning and optimization, real time performance and control, service recovery, retail services, incident management, retail services, and asset management; and infrastructure software services that include safety management, planning and delivery of work, remote condition monitoring and data acquisition, and asset virtualization/intelligent infrastructure/digital railway. This segment also offers transit and ticketing solutions, including passenger analytics, retail operations, and delay repay. The Data, Analytics, Consultancy & Events segment provides informatics and location analytics, which include geographical information systems, data visualization and analytics platforms, and asset management; transport data and analytics, such as passenger/traffic data collection, and traffic insights covering data visualization and data-as-a-service; and event traffic management solutions, such as event transport planning and traffic management, and integrated traffic data management and event access control. It serves transport operators, transport authorities, infrastructure operators, government agencies and local authorities, as well as event organizers in the United Kingdom, Ireland, rest of Europe, North America, and internationally. The company was incorporated in 2004 and is headquartered in Leeds, the United Kingdom.
Full TCIIF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.